Batten Disease Clinical Trial
— Batten'sCLN6Official title:
Natural History Study of Batten's CLN6 Disease
NCT number | NCT03285425 |
Other study ID # | IRB16-00554 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 2017 |
Est. completion date | January 2025 |
CLN6 is a rare, neurodegenerative disease that causes progressive loss of acquired skills with motor delay, visual loss, seizures and ataxia. The investigators propose a natural history study of this rare disorder since it is currently unknown. It is important to understand disease progression in CLN6 disease to be able to judge therapeutic efficacy as emerging therapies like gene therapy become available.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | January 2025 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 25 Years |
Eligibility | Inclusion Criteria: - Confirmed diagnosis of genotypic diagnosis of CLN6 Exclusion Criteria: - Patients who do not have a genotypic diagnosis of CLN6 |
Country | Name | City | State |
---|---|---|---|
United States | Nationwide Children's Hospital | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Emily de los Reyes |
United States,
Canafoglia L, Gilioli I, Invernizzi F, Sofia V, Fugnanesi V, Morbin M, Chiapparini L, Granata T, Binelli S, Scaioli V, Garavaglia B, Nardocci N, Berkovic SF, Franceschetti S. Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations. Neurology. 2015 Jul 28;85(4):316-24. doi: 10.1212/WNL.0000000000001784. Epub 2015 Jun 26. — View Citation
Gao H, Boustany RM, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, Gillis T, Qin X, Liu S, Donahue LR, Bronson RT, Faust JR, Stout D, Haines JL, Lerner TJ, MacDonald ME. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet. 2002 Feb;70(2):324-35. Epub 2001 Dec 21. — View Citation
Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases - clinical perspectives. Biochim Biophys Acta. 2013 Nov;1832(11):1801-6. doi: 10.1016/j.bbadis.2013.04.008. Epub 2013 Apr 17. — View Citation
Sharp JD, Wheeler RB, Parker KA, Gardiner RM, Williams RE, Mole SE. Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis. Hum Mutat. 2003 Jul;22(1):35-42. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Natural history of disease progression | The investigators will assess historical data for the onset of seizures, blindness, dementia, and loss of motor skills; and will request any available MRIs and EEGs. | Three years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02254863 -
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
|
Phase 1 | |
Completed |
NCT01907087 -
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03307304 -
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis
|
||
Active, not recruiting |
NCT03770572 -
Gene Therapy for Children With CLN3 Batten Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT06203106 -
NYSCF Scientific Discovery Biobank
|
||
Completed |
NCT00151268 -
Genotype - Phenotype Correlations of LINCL
|
N/A | |
Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
Completed |
NCT01035424 -
Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis
|
||
Completed |
NCT00151216 -
Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis
|
Phase 1 | |
Active, not recruiting |
NCT04273243 -
Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer
|
||
Completed |
NCT00176904 -
Stem Cell Transplant for Inborn Errors of Metabolism
|
Phase 2/Phase 3 | |
Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
Completed |
NCT02678689 -
A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
|
Phase 2 | |
Completed |
NCT02485899 -
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05174039 -
An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT01698229 -
Collection of Cerebrospinal Fluid in Healthy Children
|
N/A | |
Enrolling by invitation |
NCT03862274 -
Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease
|
||
Recruiting |
NCT01873924 -
Clinical and Neuropsychological Investigations in Batten Disease
|
||
Completed |
NCT01161576 -
Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)
|
Phase 1 | |
Recruiting |
NCT04613089 -
Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database
|